Several other brokerages have also recently issued reports on KMDA. BidaskClub upgraded shares of Kamada from a “sell” rating to a “hold” rating in a report on Friday, February 7th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Kamada has an average rating of “Hold” and a consensus price target of $8.17.
Shares of Kamada stock opened at $6.51 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.49 and a current ratio of 6.14. Kamada has a 52-week low of $4.91 and a 52-week high of $8.00. The stock has a market capitalization of $298.28 million, a price-to-earnings ratio of 7.66 and a beta of 1.36. The company’s 50 day moving average price is $6.67 and its 200-day moving average price is $6.02.
Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.13. Kamada had a net margin of 24.16% and a return on equity of 28.62%. The firm had revenue of $32.07 million for the quarter, compared to analysts’ expectations of $31.63 million. As a group, equities research analysts forecast that Kamada will post 0.55 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Eagle Ridge Investment Management bought a new stake in Kamada in the third quarter valued at $171,000. Seizert Capital Partners LLC bought a new stake in Kamada in the fourth quarter valued at $194,000. BlackRock Inc. bought a new stake in Kamada in the second quarter valued at $216,000. Marshall Wace LLP bought a new stake in Kamada in the first quarter valued at $276,000. Finally, Jane Street Group LLC boosted its holdings in Kamada by 52.8% in the fourth quarter. Jane Street Group LLC now owns 57,872 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 19,991 shares in the last quarter. Hedge funds and other institutional investors own 12.97% of the company’s stock.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Recommended Story: Trading Stocks – What are percentage gainers?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.